Integrating Immune Response into Risk Management
Regulatory evaluation of long-term implants increasingly emphasizes sustained biological performance.
Foreign body response and fibrotic encapsulation directly influence safety and clinical predictability.
Foreign Body Response as a Risk Variable
Under ISO 14971 principles, chronic inflammatory signaling may represent a hazard
mechanism contributing to performance degradation.
Addressing this mechanism proactively strengthens risk mitigation strategy.
Alignment with Biocompatibility Frameworks
Interface-modulating surface strategies must integrate within ISO 10993 evaluation, design
control documentation, and structured clinical planning.
Surface intervention should reduce biological uncertainty — not introduce systemic variability.
Structured Development
Clear mechanism documentation, preclinical validation, and indication focus support regulatory
robustness.
Interface biology belongs within the technical file.
Structured dialogue with regulatory and quality teams is welcomed.